Background: Prognosis of patients with advanced epithelial ovarian cancer (EOC) is poor. We studi... more Background: Prognosis of patients with advanced epithelial ovarian cancer (EOC) is poor. We studied case records of 43 such patients to evaluate the impact of primary and interval debulking surgery. Patients and Methods: Between January 2001 and June 2003, 43 patients underwent either primary surgery followed by chemotherapy (group A, n=23) or primary chemotherapy followed by interval debulking surgery then chemotherapy (group B, n=20). A combination of paclitaxel and cisplatin or carboplatin was used for all patients. Results: Patients median age in group A and B was 46 and 50 years, respectively. In g roup A 56.5% of patients underwent optimal cyto reduction (< 1.5cm residual tumour) compared to 30% in g roup B. Median overall survival was 24 and 14 months in group A & B, respectively, p=ns and two year probability of over survival was 61% and 50%, respectively, p = ns. Grade3-4 GI toxicity and g rade 1-2 neuropathy were main treatment related complications and were similar in both groups. CONCLUSIONS: Neoadjuvant chemotherapy results in survival rates comparable to those associated with primary cytoreductive surgery.
Background & objectives: Polycystic ovary syndrome (PCOS) is an endocrinopathy warranting lifelon... more Background & objectives: Polycystic ovary syndrome (PCOS) is an endocrinopathy warranting lifelong individualized management by lifestyle and pharmacological agents mainly oral contraceptive pills (OCPs). This study was aimed to report the impact of six-month OCP use on plasminogen activator inhibitor-1 (PAI-1) and factor VIII (FVIII) in women with PCOS. Methods: PCOS women diagnosed on the basis of Rotterdam 2003 criteria, either treated with OCPs (ethinyl estradiol-0.03 mg, levonorgestrel-0.15 mg) for a period of six months (n=40) or drug-naïve (n=42), were enrolled in this study. Blood was drawn to estimate glucose, insulin levels and lipid profile. Chemiluminescence immunoassays were used to measure hormones (LH, FSH, PRL, T4). Plasma levels of PAI-I and FVIII were measured by commercially available kits. Results: Menstrual regularity, Ferriman-Gallwey score and serum total testosterone significantly improved in the OCP group compared to drug-naïve group (P<0.01). No signific...
International journal of current research and review, 2016
Objectives: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are important transfusion-transmi... more Objectives: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are important transfusion-transmissible infections. This study was performed to assess the Seropositivity of HBV and HCV Seropositivity among blood donors at a Tertiary Care Hospital based blood bank at SKIMS, Kashmir. Materials and Methods: The blood donation records over 10 years from Jan2003 to Dec-2012 were reviewed, retrospectively, for the seropositivity and yearly trends of HBV and HCV. Results: A total of 97427 donations were received. The overall number of HBV seropositive donations was 469 and that for HCV was 194, with the seroprevalence rates of 0.48% for hepatitis B surface antigen (HBsAg) and 0.20% for HCV. The seropositivity rate was higher in the replacement donors compared to the voluntary donors and 0% in repeat voluntary donors. The annual rates showed decreasing trends for both HBsAg and HCV. Conclusion: The seropositivity of viral markers was lower in our study as compared with studies from other pa...
The phenomenon of imatinib resistance in Chronic Myeloid Leukemia (CML) can be mediated by "BCR-A... more The phenomenon of imatinib resistance in Chronic Myeloid Leukemia (CML) can be mediated by "BCR-ABL fusion transcript dependent" and "BCR-ABL fusion transcript independent" pathways. The main means of "BCR-ABL fusion transcript dependent" pathway, responsible for 40-90% of such cases, is the occurrence of Kinase Domain (KD) mutations. The aim of this study was to evaluate the commonly occurring KD mutations like G250, Y253, E255, T315, F317, M351, F359, and H396 for imatinib resistance in CML patients from Kashmir (North India). A total of 42 confirmed cases of CML were subjected to reverse transcriptase polymerase chain reaction (RT-PCR). Kinase Domain PCR-amplicons, derived from the amplification of respective patient's cDNA following reverse transcription of BCR-ABL fusion mRNA, were subjected to nucleotide sequence analysis by 'Genetic Analyser' sequencing platform ABI 3500. CML patients included 18 males (42.85%) and 24 females (57.14%) aged from 7 to 75 years, of which 19 cases (45.23%) belonged to age group of ≤45 years and the rest 23 cases (54.76%) were > 45 years of age. Sequence analysis was carried out to all the 42 patients at baseline and only on suspected resistant cases at designated follow-ups of 3 months, 6 months and one year. The overall incidence of imatinib resistance in our patients was very low as there were only 8 patients (19.04%), of which 6 cases (14.28%) reported with 'No cytogenetic response' (NCR) at 3 months and 1 each having lost earlier attained 'Complete cytogenetic response' (CCR) and molecular response at 6 months. These 8 patients were enlisted as suspected imatinib resistant cases and were subjected to imatinib resistance mutation analysis (IRMA) by sequencing at successive designated follow-up periods as applicable. No imatinib resistance mutations were detected in the patients either at baseline or across all the follow-up durations implying other causes for imatinib resistance in CML patients of our region.
Molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR is increasingly b... more Molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR is increasingly being used to diagnose the disease and assess treatment response in patients with chronic myeloid leukemia (CML). This has become particularly relevant when residual levels of leukemia usually fall below the level of detection by cytogenetic analysis. Forty-two CML patients, including 18 males (42.86%) and 24 females (57.14%) aged 7-75 years, were enlisted for the study and followed-up for the response to imatinib treatment. Patients were subjected to Multiplex RT-PCR (reverse-transcriptase PCR) and were all found to harbor either e13a2 or the e14a2, which could be analyzed by a single Taqman probe based quantitation kit (Geno-Sen's) to quantitate the BCR-ABL transcript load. The Multiplex RT-PCR and peripheral blood cytogenetics providing specific and sensitive detection of BCR-ABL fusion transcripts and metaphase signal load respectively were used as parallel reference tools to auth...
Factor XIII deficiency is a rare disorder and these patients present with bleeding diathesis in t... more Factor XIII deficiency is a rare disorder and these patients present with bleeding diathesis in the neonatal period. An 18 days old male child was brought with the history of umbilical stump bleeding. Two previous siblings had died in the neonatal period of an unknown cause, possibly because of intracranial haemorrhage and another at the age of 6 years of unknown cause. Investigations revealed Factor XIII deficiency. He was put on Fresh Frozen Plasma (FFP) support as he could not afford Fibrogammin and currently receives 6 weekly FFP and is doing well. J Med Sci 2009;12(2):53-55.
Asian Pacific journal of cancer prevention : APJCP, 2012
Cancer is a complex disease and the genetic susceptibility to it could be an outcome of the inher... more Cancer is a complex disease and the genetic susceptibility to it could be an outcome of the inherited difference in the capacity of xenobiotic metabolizing enzymes. Glutathione-S-transferases (GSTs) are phase II metabolizing enzymes whose various genotypes have been associated with increased risk of different types of cancer. Null mutations caused by the deletion of the entire gene result in the absence of the enzymatic activity and increase in the risk of developing cancer including chronic myeloid leukaemia (CML). In the present case-control study we evaluated the effect of null mutations in GSTM1 and GSTT1 genes on the risk of developing CML. The study included 75 CML patients (43 males and 32 females; age (mean ± S.D) 42.3 ± 13.4 years) and unrelated non-malignant controls (76 male and 48 females; age (mean ± S.D) 41.5 ± 12.9). The distribution of GSTM1 and GSTT1 genotypes in CML patients and controls was assessed by multiplex-PCR method. Logistic regression was used to assess t...
Indian Journal of Hematology and Blood Transfusion, 2010
A large cell lymphoma develops in approximately 1-10% of chronic lymphocytic leukemia (CLL). This... more A large cell lymphoma develops in approximately 1-10% of chronic lymphocytic leukemia (CLL). This is known as Richter's syndrome. Chest wall swelling is a very unusual presentation of this syndrome. Here we report another such case of chest wall swelling, a very rare presentation of Richter's syndrome.
Indian Journal of Medical and Paediatric Oncology, 2008
... Primary non-hodgkin&#x27;s lymphoma of breast Abdul Rashid Lone 1 , Mushtaq Ahmad 1 , She... more ... Primary non-hodgkin&#x27;s lymphoma of breast Abdul Rashid Lone 1 , Mushtaq Ahmad 1 , SheikhAejaz Aziz 1 , Samoon Jeelani 2 , Rifat Jehan 1 , Javid Rasool Bhat 2 1 Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Post Bag. ...
Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased... more Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. Twenty of 3,600 (0.56 %) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 %) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 %) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.
Background: Prognosis of patients with advanced epithelial ovarian cancer (EOC) is poor. We studi... more Background: Prognosis of patients with advanced epithelial ovarian cancer (EOC) is poor. We studied case records of 43 such patients to evaluate the impact of primary and interval debulking surgery. Patients and Methods: Between January 2001 and June 2003, 43 patients underwent either primary surgery followed by chemotherapy (group A, n=23) or primary chemotherapy followed by interval debulking surgery then chemotherapy (group B, n=20). A combination of paclitaxel and cisplatin or carboplatin was used for all patients. Results: Patients median age in group A and B was 46 and 50 years, respectively. In g roup A 56.5% of patients underwent optimal cyto reduction (< 1.5cm residual tumour) compared to 30% in g roup B. Median overall survival was 24 and 14 months in group A & B, respectively, p=ns and two year probability of over survival was 61% and 50%, respectively, p = ns. Grade3-4 GI toxicity and g rade 1-2 neuropathy were main treatment related complications and were similar in both groups. CONCLUSIONS: Neoadjuvant chemotherapy results in survival rates comparable to those associated with primary cytoreductive surgery.
Background & objectives: Polycystic ovary syndrome (PCOS) is an endocrinopathy warranting lifelon... more Background & objectives: Polycystic ovary syndrome (PCOS) is an endocrinopathy warranting lifelong individualized management by lifestyle and pharmacological agents mainly oral contraceptive pills (OCPs). This study was aimed to report the impact of six-month OCP use on plasminogen activator inhibitor-1 (PAI-1) and factor VIII (FVIII) in women with PCOS. Methods: PCOS women diagnosed on the basis of Rotterdam 2003 criteria, either treated with OCPs (ethinyl estradiol-0.03 mg, levonorgestrel-0.15 mg) for a period of six months (n=40) or drug-naïve (n=42), were enrolled in this study. Blood was drawn to estimate glucose, insulin levels and lipid profile. Chemiluminescence immunoassays were used to measure hormones (LH, FSH, PRL, T4). Plasma levels of PAI-I and FVIII were measured by commercially available kits. Results: Menstrual regularity, Ferriman-Gallwey score and serum total testosterone significantly improved in the OCP group compared to drug-naïve group (P<0.01). No signific...
International journal of current research and review, 2016
Objectives: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are important transfusion-transmi... more Objectives: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are important transfusion-transmissible infections. This study was performed to assess the Seropositivity of HBV and HCV Seropositivity among blood donors at a Tertiary Care Hospital based blood bank at SKIMS, Kashmir. Materials and Methods: The blood donation records over 10 years from Jan2003 to Dec-2012 were reviewed, retrospectively, for the seropositivity and yearly trends of HBV and HCV. Results: A total of 97427 donations were received. The overall number of HBV seropositive donations was 469 and that for HCV was 194, with the seroprevalence rates of 0.48% for hepatitis B surface antigen (HBsAg) and 0.20% for HCV. The seropositivity rate was higher in the replacement donors compared to the voluntary donors and 0% in repeat voluntary donors. The annual rates showed decreasing trends for both HBsAg and HCV. Conclusion: The seropositivity of viral markers was lower in our study as compared with studies from other pa...
The phenomenon of imatinib resistance in Chronic Myeloid Leukemia (CML) can be mediated by "BCR-A... more The phenomenon of imatinib resistance in Chronic Myeloid Leukemia (CML) can be mediated by "BCR-ABL fusion transcript dependent" and "BCR-ABL fusion transcript independent" pathways. The main means of "BCR-ABL fusion transcript dependent" pathway, responsible for 40-90% of such cases, is the occurrence of Kinase Domain (KD) mutations. The aim of this study was to evaluate the commonly occurring KD mutations like G250, Y253, E255, T315, F317, M351, F359, and H396 for imatinib resistance in CML patients from Kashmir (North India). A total of 42 confirmed cases of CML were subjected to reverse transcriptase polymerase chain reaction (RT-PCR). Kinase Domain PCR-amplicons, derived from the amplification of respective patient's cDNA following reverse transcription of BCR-ABL fusion mRNA, were subjected to nucleotide sequence analysis by 'Genetic Analyser' sequencing platform ABI 3500. CML patients included 18 males (42.85%) and 24 females (57.14%) aged from 7 to 75 years, of which 19 cases (45.23%) belonged to age group of ≤45 years and the rest 23 cases (54.76%) were > 45 years of age. Sequence analysis was carried out to all the 42 patients at baseline and only on suspected resistant cases at designated follow-ups of 3 months, 6 months and one year. The overall incidence of imatinib resistance in our patients was very low as there were only 8 patients (19.04%), of which 6 cases (14.28%) reported with 'No cytogenetic response' (NCR) at 3 months and 1 each having lost earlier attained 'Complete cytogenetic response' (CCR) and molecular response at 6 months. These 8 patients were enlisted as suspected imatinib resistant cases and were subjected to imatinib resistance mutation analysis (IRMA) by sequencing at successive designated follow-up periods as applicable. No imatinib resistance mutations were detected in the patients either at baseline or across all the follow-up durations implying other causes for imatinib resistance in CML patients of our region.
Molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR is increasingly b... more Molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR is increasingly being used to diagnose the disease and assess treatment response in patients with chronic myeloid leukemia (CML). This has become particularly relevant when residual levels of leukemia usually fall below the level of detection by cytogenetic analysis. Forty-two CML patients, including 18 males (42.86%) and 24 females (57.14%) aged 7-75 years, were enlisted for the study and followed-up for the response to imatinib treatment. Patients were subjected to Multiplex RT-PCR (reverse-transcriptase PCR) and were all found to harbor either e13a2 or the e14a2, which could be analyzed by a single Taqman probe based quantitation kit (Geno-Sen's) to quantitate the BCR-ABL transcript load. The Multiplex RT-PCR and peripheral blood cytogenetics providing specific and sensitive detection of BCR-ABL fusion transcripts and metaphase signal load respectively were used as parallel reference tools to auth...
Factor XIII deficiency is a rare disorder and these patients present with bleeding diathesis in t... more Factor XIII deficiency is a rare disorder and these patients present with bleeding diathesis in the neonatal period. An 18 days old male child was brought with the history of umbilical stump bleeding. Two previous siblings had died in the neonatal period of an unknown cause, possibly because of intracranial haemorrhage and another at the age of 6 years of unknown cause. Investigations revealed Factor XIII deficiency. He was put on Fresh Frozen Plasma (FFP) support as he could not afford Fibrogammin and currently receives 6 weekly FFP and is doing well. J Med Sci 2009;12(2):53-55.
Asian Pacific journal of cancer prevention : APJCP, 2012
Cancer is a complex disease and the genetic susceptibility to it could be an outcome of the inher... more Cancer is a complex disease and the genetic susceptibility to it could be an outcome of the inherited difference in the capacity of xenobiotic metabolizing enzymes. Glutathione-S-transferases (GSTs) are phase II metabolizing enzymes whose various genotypes have been associated with increased risk of different types of cancer. Null mutations caused by the deletion of the entire gene result in the absence of the enzymatic activity and increase in the risk of developing cancer including chronic myeloid leukaemia (CML). In the present case-control study we evaluated the effect of null mutations in GSTM1 and GSTT1 genes on the risk of developing CML. The study included 75 CML patients (43 males and 32 females; age (mean ± S.D) 42.3 ± 13.4 years) and unrelated non-malignant controls (76 male and 48 females; age (mean ± S.D) 41.5 ± 12.9). The distribution of GSTM1 and GSTT1 genotypes in CML patients and controls was assessed by multiplex-PCR method. Logistic regression was used to assess t...
Indian Journal of Hematology and Blood Transfusion, 2010
A large cell lymphoma develops in approximately 1-10% of chronic lymphocytic leukemia (CLL). This... more A large cell lymphoma develops in approximately 1-10% of chronic lymphocytic leukemia (CLL). This is known as Richter's syndrome. Chest wall swelling is a very unusual presentation of this syndrome. Here we report another such case of chest wall swelling, a very rare presentation of Richter's syndrome.
Indian Journal of Medical and Paediatric Oncology, 2008
... Primary non-hodgkin&#x27;s lymphoma of breast Abdul Rashid Lone 1 , Mushtaq Ahmad 1 , She... more ... Primary non-hodgkin&#x27;s lymphoma of breast Abdul Rashid Lone 1 , Mushtaq Ahmad 1 , SheikhAejaz Aziz 1 , Samoon Jeelani 2 , Rifat Jehan 1 , Javid Rasool Bhat 2 1 Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Post Bag. ...
Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased... more Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. Twenty of 3,600 (0.56 %) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 %) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 %) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.
Uploads
Papers by Samoon Jeelani